3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
5
Gastrointestinal
4
Thoracic
2
Breast
2
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Conditions
Advanced Solid Tumors
479
Solid Tumor
416
Advanced Solid Tumor
407
Unspecified Adult Solid Tumor, Protocol Specific
350
Solid Tumors
321
Mesothelioma, Malignant
281
Mesothelioma
244
Solid Tumor, Adult
113
Carcinoma, Non-Small-Cell Lung
109
Retinoblastoma
81
Ovarian Neoplasms
65
Lung Neoplasms
61
Melanoma
56
Sarcoma
52
Stomach Neoplasms
50
Carcinoma, Renal Cell
49
Colorectal Neoplasms
46
Small Cell Lung Carcinoma
45
Pancreatic Neoplasms
45
Esophageal Neoplasms
45
Neoplasms
43
Uterine Cervical Neoplasms
41
Breast Neoplasms
38
Advanced or Metastatic Solid Tumors
35
Neoplasm Metastasis
33
Hematopoietic and Lymphatic System Neoplasm
33
Squamous Cell Carcinoma of Head and Neck
32
Solid Tumours
30
Advanced Malignant Solid Tumors
30
Triple Negative Breast Neoplasms
29
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Tertiary Lymphoid Structures
×
Other solid neoplasm
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled